E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/6/2006 in the Prospect News Biotech Daily.

Affymetrix maintained by Merrill at sell

Affymetrix Inc. was maintained by Merrill Lynch analyst J. Darryl Pardi at a sell rating. Merrill reduced earnings-per-share estimates in light of the company's anticipated slower revenue growth. Management expects consolidated revenues to grow 15% this year versus Merrill's prior forecast of 22% growth. The company's outlook is disappointing relative to management's optimism during 2005 and because the company has one of the most robust new product portfolios in the history of the company. Shares of the Santa Clara, Calif., maker of scientific and technical instruments were down $3.63, or 7.74%, at $43.27 on volume of 6,199,823 shares versus the three-month running average of 980,894 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.